Dignify Therapeutics, a drug development company focused on restoring bladder and bowel control for the elderly and for people with spinal injury, multiple sclerosis or diabetes, continues to draw federal grants from the National Institutes of Health for its research and development.
We work hard to bring you the stories about the life science community in North Carolina. Every once in a while, we add a little news of our own. Read some of those stories below, or check out some of our perspectives on our staff blog.
The North Carolina Biotechnology Center is hosting the second annual VaccinatioNCelebration flu shot clinic all day Tuesday, Oct. 17, 2017, to highlight North Carolinians’ production of the newest generation of flu vaccine.
BioreclamationIVT, a New York company that sells biospecimens and related services, primarily for drug safety testing, has purchased Durham’s Qualyst Transporter Solutions for an undisclosed sum.
Raleigh-based Innovate Biopharmaceuticals has received U.S. Food and Drug Administration orphan drug designation for an experimental oral drug to treat pediatric ulcerative colitis.
Jack Bailey, president of U.S. Pharmaceuticals for GlaxoSmithKline, says an internship he served at the Biotech Center was a major influence in his successful career as a global pharmaceutical company leader.
Sixteen life science companies throughout North Carolina have received just over $1 million in grants from a state program to support their development of new technologies and products.
A $76,527 Institutional Development Grant from the North Carolina Biotechnology Center earlier in 2017 has given Western North Carolina university scientists and students access to an important new research tool.
Durham-based Grid Therapeutics, an oncology-focused biotechnology company, has signed an exclusive license agreement with Duke University to develop the first human-derived antibody as a targeted immunotherapy for cancer.
The North Carolina Biotechnology Center awarded 47 loans and grants totaling $3.6 million to universities, bioscience companies and other entities in the fourth quarter of its 2016-2017 fiscal year ending June 30.
Eighteen bioscience companies previously funded by NCBiotech loans raised more than $128 million in follow-on funding from other sources during the fourth quarter of 2016-17.
A $75,000 grant from the North Carolina Biotechnology Center is helping Duke University researchers develop a cervical cancer screening tool that women everywhere might be able to use on themselves.